CompletedNot Applicable

The Safety and Efficacy of RIC on Adult Moyamoya Disease

China30 participantsStarted 2019-07-15

Plain-language summary

There are a series of symptoms such as ischemic stroke、transient ischemic attack 、hemorrhagic stroke、headache 、seizure and so on in moyamoya disease( MMD) patients .Nowadays, revascularization is the only effective way for ischemic MMD and there is no effective conservative treatment for MMD. This study was to explore the safety and efficacy of remote ischemic conditioning(RIC ) on adult MMD patients.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age: 18-60 years * All of the patients underwent digital subtraction angiography (DSA) and met the current diagnostic criteria recommended by the Research Committee on MMD of the Ministry of Health and Welfare of Japan in 2012. * mRs≤3 * Informed consent obtained from patient or acceptable patient's surrogate. Exclusion Criteria: * Patients with acute ischemic or hemorrhagic stroke within 3 months. * Severe hepatic or renal dysfunction. * Severe hemostatic disorder or severe coagulation dysfunction. * Severe cardiac diseases. * Patients with severe existing neurological or psychiatric disease * Patients with moyamoya syndrome caused by autoimmune disease, Down syndrome , neurofibromatosis, leptospiral infection, or previous skull-base radiation therapy. * Patients have been done or plan to accept revascularization surgery.

What they're measuring

improvement ratio of mean cerebral blood flow

Timeframe: change from the baseline to12 months after treatment

Trial details

NCT IDNCT04012268

SponsorCapital Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-11-10

View on ClinicalTrials.gov More Moyamoya Disease trials